Cannabis Law Report

DECEMBER 15, 2021

The importation of the naturally derived psilocybin into California was completed after the Company’s supply partner Mycrodose Therapeutics was granted an import license from the United States Drug Enforcement Administration (DEA). “With their track-record of working with the U.S. . About Mycrodose Therapeutics.

Supply Chain 52

Supply Chain Research and Development DEA Pharmaceutical 52

SpeedWeed

AUGUST 8, 2021

It’s the first cannabis-derived pharmaceutical to be legalized in many countries around the world, including the UK, Spain, United States, Canada, and New Zealand. . If all goes according to plan, patients will receive Sativex and the temozolomide chemotherapy drug, temozolomide on its own, or a placebo.

Cannabinoids 64

Cannabinoids Pharmaceutical DEA Medicine 64

Canna Law Blog

AUGUST 21, 2020

Although the Second Circuit expressed considerable skepticism of the drug scheduling regime, the court held that before plaintiffs could seek relief in federal court, they must first file a de-scheduling petition with the DEA. At this point, readers may be asking: Why didn’t the plaintiffs file a petition with the DEA? Petition at 3.

DEA 69

DEA Marijuana Pharmaceutical Cannabis 69

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “It also creates new opportunities for researchers, entrepreneurs, investors and pharmaceutical companies.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

MedicalJane

MAY 14, 2020

As a result, research on the health effects of cannabis and cannabinoids has been limited in the United States, leaving patients, healthcare professionals, and policy makers without the necessary proof they need to make sound decisions regarding the use of cannabis as a medicine.

Sleep 95

Sleep Edibles DEA Policy 95

Cannabis Law Report

JULY 7, 2019

These are many of the common questions and concerns your average patient has with respect to cannabis today and the answer isn’t quite as clear as we would like it to be; however, there is a linguistic trend steering towards the term “medicated” to replace, the pejorative, “high” for cannabis users seeking medical relief. AUTHOR: Anthony S.

DEA 40

DEA Pharmaceutical Conditions Patients 40

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. ”, our first instinct is to remain patients that CBD is CBD.

CBD 99

CBD DEA Research and Development Hemp 99

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

SpeedWeed

JULY 23, 2021

Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials. The license only allows MedPharm to conduct research on cannabis that was shifted through certain channels that have been approved by the government and DEA.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

SpeedWeed

AUGUST 11, 2021

This trial will be the second of its kind to be conducted so far, and one that is an FDA- and DEA-regulated double-blind, placebo-controlled study. Results of this study showed evidence of the pros and cons to cannabis as a treatment for PTSD patients. The study was funded with $2.2 PTSD affects a large number of military veterans.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

The Blunt Truth

OCTOBER 3, 2019

They maintain that the limits will put constraints on the amount of marijuana available to patients. GW Pharmaceuticals and Montefiore Medical Center in New York are teaming up to study the use of a cannabis compound on autism. Also in New Mexico , growers of medical cannabis are suing the state over limits on plant-count.

Chronic Pain 77

Chronic Pain Hemp DEA Programs 77

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

APRIL 1, 2019

Selling dried cannabis to pharmaceutical companies as well as Cannabidiol (CBD) and Tetrahydrocannabinol (THC) extracts as soon as it is licensed, is the intention of Thailand’s tobacco authority among new measures to turn a profit on its dwindling cigarette business. 49 Percent Foreign Shareholding Allowed. GPO, the Ultra-Modern Drug Maker.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

Veriheal

DECEMBER 28, 2021

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. For example, pharmaceutical-grade cannabis is being sold across the fast-evolving retail pharmacy landscape.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . 30,000 patient doses) of MDMA in a four-step process beginning with a non-controlled starting material. The chemical purity of the final product exceeded 99.9%

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

The Cannigma

MAY 1, 2023

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. It was also after the Vietnam War that widespread ketamine abuse would begin to show up as a party drug.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Veriheal

JUNE 29, 2021

While they offer approved clinical trials that can offer patients the ability to try potential therapeutic options, many patients are unable to participate in clinical trials, and this is where the importance of the Right to Try programs comes into play. A Push by Patients. Patients Are Not In This Alone.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA 59

DEA Pharmaceutical Research and Development Compliance 59

Weedistry

MARCH 7, 2019

Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies. A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings.

THC 40

THC CBD Clinical Trials Research and Development 40

Canna Law Blog

SEPTEMBER 6, 2023

Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). Just my two cents; feel free to disagree.

Research and Development 113

Research and Development DEA Marijuana Pharmaceutical 113

Cannabis Law Report

JUNE 10, 2021

–(BUSINESS WIRE)– CURE Pharmaceutical Holding Corp. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. OXNARD, Calif.–(BUSINESS

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

Cannabis Law Report

FEBRUARY 28, 2022

Show More According to the Drug Enforcement Administration (DEA), Schedule I drugs have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.” 10, 2019), [link] [ [link] ]. It contains five Parts. Part II analyzes how U.S.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Cheri

DECEMBER 17, 2021

Locate a nurse and ask how many patients are in the respiratory wing due to their use of tobacco. You will learn that most of the patients in that wing are there for that reason. Now ask how many patients are there because they only smoked marijuana. This article is all about the effects of marijuana on the lungs.

Marijuana 246

Marijuana Media Patients DEA 246

Cannabis Law Report

SEPTEMBER 20, 2019

DEA increases the cannabis research quota. The Drug Enforcement Administration (DEA) announced annual quotas for the manufacture of controlled substances for research purposes, providing for 7,000 pounds of cannabis to be used in scientific studies. The state has issued 8,000 patient and caregiver ID cards since June 28.

Vaping 40

Vaping Banking Research and Development DEA 40

Canna Law Blog

MAY 7, 2020

What you may not know is that the federal government actually has its own stash of cannabis for limited patient distribution and limited research purposes that it houses at the University of Mississippi (a/k/a) Ole Miss in Oxford, Mississippi. These cannabis products are used by researchers in the U.S.

DEA 71

DEA Research and Development Cultivation Supply Chain 71

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. “ Off-label use ” (which is extremely common) is: the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Cheri

DECEMBER 17, 2021

Locate a nurse and ask how many patients are in the respiratory wing due to their use of tobacco. You will learn that most of the patients in that wing are there for that reason. Now ask how many patients are there because they only smoked marijuana. This article is all about the effects of smoking marijuana and lung health.

Marijuana 130

Marijuana Media Patients DEA 130

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. “ Off-label use ” (which is extremely common) is: the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

SpeedWeed

MARCH 28, 2021

That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”. As a result, there has been more interest among patients, clinicians, and researchers to see if cannabis is effective in treating PTSD. . Many veterans with PTSD already use cannabis to self-treat their symptoms.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Cannabis Law Report

JULY 1, 2021

Things have changed a little in the past twenty years, when the DEA gave some researchers permission to study limited amounts of certain psychedelics. But they remain relatively small, in part because the DEA limits the amount of psilocybin and other psychedelics that can be produced each year. Who might be left behind?

Law 105

Law Research and Development Therapy DEA 105

The Cannigma

SEPTEMBER 12, 2021

Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only. Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. Full spectrum.

THC 98

THC Research and Development Cannabinoids CBD 98

Sensi Seeds

NOVEMBER 28, 2018

The confusion is compounded by the fact another CBD company, GW Pharmaceuticals, the British Biotech and marijuana grower, managed to secure approval from the U.S. CBD Regulation is Needed.

CBD 71

CBD Seed-To-Sale Food Research and Development 71

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

JUNE 15, 2021

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved, as an industry, and as a drug, for the elite. GW Pharmaceuticals was just awarded a so-called “ Queen’s Prize for Innovation.” .

Pharmaceutical 40

Pharmaceutical Chronic Pain Epilepsy Patients 40